Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax Plus Zanubrutinib in Relapsed/Refractory Mantle Cell Lymphoma Planned for CAR-T Cell Therapy
NCT07341191Phase 2Recruiting
- Sponsor
- Canadian Cancer Trials Group
- Start
- Aug 2026
- Primary completion
- Dec 2029
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sonrotoclax and zanubrutinib in mantle cell lymphoma (MCL), sponsored by Canadian Cancer Trials Group. Primary endpoint: Complete response post CAR-T at 3.5 years. Started Aug 2026; status: recruiting.
02
Drugs
sonrotoclaxzanubrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT07341191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07341191.